Floatz logo

Dostarlimab

Rectal Neoplasm Malignant

University of Iowamonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

69 Active assets in the Rectal Neoplasm Malignant cohort.

Asset / SponsorPhaseRating
Irinotecan
Sun Yat-sen University
Phase 4BBB
FLUOROURACILUM
Seoul National University Hospital
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Tao Zhang
Phase 3BB

View all 50 →

Same molecule, other indications

Dostarlimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Neoplasms, ColonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →